nach oben

Erschienen in:

26.11.2018 | Original Article

Can benign lymphoid tissue changes in ¹⁸F-FDG PET/CT predict response to immunotherapy in metastatic melanoma?

verfasst von: Christos Sachpekidis, Lionel Larribère, Annette Kopp-Schneider, Jessica C. Hassel, Antonia Dimitrakopoulou-Strauss

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

An association between immune-related adverse events (irAEs) caused by immunotherapeutic agents and the clinical benefit of immunotherapy has been suggested. We retrospectively evaluated by means of ¹⁸F-FDG PET/CT lymphoid tissue changes in the mediastinal/hilar lymph nodes and the spleen in response to ipilimumab administration in metastatic melanoma.

Methods

A total of 41 patients with unresectable metastatic melanoma underwent ¹⁸F-FDG PET/CT before the start of ipilimumab (baseline PET/CT), after two cycles (interim PET/CT) and at the end of treatment (late PET/CT). Data analysis was focused on the mediastinal/hilar lymph nodes and the spleen. The patients’ best clinical response (BCR) was used as reference.

Results

According to the BCR reference, 31 patients showed disease control (DC) and 10 patients showed progressive disease (PD). Mediastinal/hilar lymph node evaluation revealed that in total 4 patients in the interim or late PET/CT (10%) demonstrated a ‘sarcoid-like lymphadenopathy’ as response to treatment (LN-positive). All LN-positive patients responded to ipilimumab with DC. On the other hand, no significant differences between the DC and PD groups regarding both semi-quantitative and quantitative ¹⁸F-FDG PET spleen-related parameters at baseline and as response to treatment were detected.

Conclusion

Based on our findings, 10% patients in the interim or late PET/CT showed ‘sarcoid-like lymphadenopathy’ as response to treatment. All these patients showed disease control, implying a relation between the appearance of sarcoid-like lymphadenopathy and the clinical benefit of anti-CTLA-4 therapy. On the other hand, quantitative ¹⁸F-FDG PET analysis of the spleen showed a poor performance in predicting clinical benefit to ipilimumab.

Downey SG, Klapper JA, Smith FO et al (2007) Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 13(22 Pt 1):6681–6688CrossRefPubMedPubMedCentral

Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723CrossRefPubMedPubMedCentral

Postow MA, Chesney J, Pavlick AC et al (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372:2006–2017CrossRefPubMedPubMedCentral

Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23–34CrossRefPubMedPubMedCentral

Weber JS, Kähler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30(21):2691–2697CrossRefPubMed

Attia P, Phan GQ, Maker AV et al (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23(25):6043–6053CrossRefPubMed

Kaehler KC, Piel S, Livingstone E, Schilling B, Hauschild A, Schadendorf D (2010) Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin Oncol 37(5):485–498CrossRefPubMed

Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T (1992) Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 33:1972–1980PubMed

Gamelli RL, Liu H, He LK, Hofmann CA (1996) Augmentations of glucose uptake and glucose transporter-1 in macrophages following thermal injury and sepsis in mice. J Leukoc Biol 59:639–647CrossRefPubMed

10.

Mochizuki T, Tsukamoto E, Kuge Y et al (2001) FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med 42:1551–1555PubMed

11.

Zhuang H, Alavi A (2002) 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med 32:47–59CrossRefPubMed

12.

Paik JY, Lee KH, Choe YS et al (2004) Augmented 18F-FDG uptake in activated monocytes occurs during the priming process and involves tyrosine kinases and protein kinase C. J Nucl Med 45:124–128PubMed

13.

Jamar F, Buscombe J, Chiti A et al (2013) EANM/SNMMI guideline for 18F-FDG use in inflammation and infection. J Nucl Med 54(4):647–658CrossRefPubMed

14.

Wong ANM, McArthur GA, Hofman MS, Hicks RJ (2017) The advantages and challenges of using FDG PET/CT for response assessment in melanoma in the era of targeted agents and immunotherapy. Eur J Nucl Med Mol Imaging 44(Suppl 1):67–77CrossRefPubMed

15.

Balch CM, Gershenwald JE, Soong S-J et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199–6206CrossRefPubMedPubMedCentral

16.

Anwar H, Sachpekidis C, Winkler J et al (2018) Absolute number of new lesions in 18F-FDG PET/CT is more predictive of clinical outcome than SUV changes in metastatic melanoma patients receiving ipilimumab. Eur J Nucl Med Mol Imaging 45(3):376–383CrossRefPubMed

17.

Sachpekidis C, Anwar H, Winkler J et al (2018) The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma. Eur J Nucl Med Mol Imaging 45(8):1289–1296CrossRefPubMed

18.

Sachpekidis C, Anwar H, Winkler JK et al (2018) Longitudinal studies of the 18F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET/CT. Cancer Immunol Immunother 67:1261–1270. https://doi.org/10.1007/s00262-018-2183-3. (Epub ahead of print)CrossRefPubMed

19.

Sokoloff L, Smith CB (1983) Basic principles underlying radioisotopic methods for assay of biochemical processes in vivo. In: Greitz T, Ingvar DH, Widén L (eds) The metabolism of the human brain studied with positron emission tomography. Raven Press, New York, pp 123–148

20.

Ohtake T, Kosaka N, Watanabe T et al (1991) Noninvasive method to obtain input function for measuring tissue glucose utilization of thoracic and abdominal organs. J Nucl Med 32:1432–1438PubMed

21.

Miyazawa H, Osmont A, Petit-Taboué MC et al (1993) Determination of 18F-fluoro-2-deoxy-d-glucose rate constants in the anesthetized baboon brain with dynamic positron tomography. J Neurosci Methods 50:263–272CrossRefPubMed

22.

Burger C, Buck A (1997) Requirements and implementation of a flexible kinetic modeling tool. J Nucl Med 38:1818–1823PubMed

23.

Sachpekidis C, Thieke C, Askoxylakis V et al (2015) Combined use of (18)F-FDG and (18)F-FMISO in unresectable non-small cell lung cancer patients planned for radiotherapy: a dynamic PET/CT study. Am J Nucl Med Mol Imaging 5(2):127–142PubMedPubMedCentral

24.

Dimitrakopoulou-Strauss A, Strauss LG, Mikolajczyk K, Burger C, Lehnert T, Bernd L, Ewerbeck V (2003) On the fractal nature of dynamic positron emission tomography (PET) studies. World J Nucl Med 2:306–313

25.

Bronstein Y, Ng CS, Hwu P, Hwu WJ (2011) Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. Am J Roentgenol 197(6):W992–W1000CrossRef

26.

Kwak JJ, Tirumani SH, Van den Abbeele AD, Koo PJ, Jacene HA (2015) Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events. Radiographics 35(2):424–437CrossRefPubMed

27.

Howard SA, Krajewski KM, Jagannathan JP et al (2016) A new look at toxicity in the era of precision oncology: imaging findings, their relationship with tumor response, and effect on metastasectomy. Am J Roentgenol 207(1):4–14CrossRef

28.

MacDonald IC, Ragan DM, Schmidt EE, Groom AC (1987) Kinetics of red blood cell passage through interendothelial slits into venous sinuses in rat spleen, analyzed by in vivo microscopy. Microvasc Res 33:118–134CrossRefPubMed

29.

Bratosin D, Mazurier J, Tissier JP et al (1998) Cellular and molecular mechanisms of senescent erythrocyte phagocytosis by macrophages. A review. Biochimie 80(2):173–195. (Review)CrossRefPubMed

30.

Yin Y, Choi SC, Xu Z et al (2015) Normalization of CD41 T cell metabolism reverses lupus. Sci Transl Med 7:274ra18CrossRefPubMedPubMedCentral

31.

Ahn SS, Hwang SH, Jung SM et al (2017) Evaluation of spleen glucose metabolism using 18F-FDG PET/CT in patients with febrile autoimmune disease. J Nucl Med 58(3):507–513CrossRefPubMed

32.

Sachpekidis C, Larribere L, Kopp-Schneider A, Haberkorn U, Hassel J, Dimitrakopoulou-Strauss A (2018) Benign lymphoid tissue changes as response to immunotherapy in metastatic melanoma patients: an 18F-FDG PET/CT study. Eur J Nucl Med Mol Imaging 45 (Suppl 1): S517 (Abstract EP-0551)

33.

Ribas A, Benz MR, Allen-Auerbach MS et al (2010) Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab. J Nucl Med 51:340–346CrossRefPubMed

34.

Tsai KK, Pampaloni MH, Hope C et al (2016) Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade. J Immunother Cancer 4:58CrossRefPubMedPubMedCentral

35.

Pektor S, Hilscher L, Walzer KC et al (2018) In vivo imaging of the immune response upon systemic RNA cancer vaccination by FDG-PET. EJNMMI Res 8(1):80CrossRefPubMedPubMedCentral

36.

Eshghi N, Garland LL, Nia E, Betancourt R, Krupinski E, Kuo PH (2018) 18F-FDG PET/CT can predict development of thyroiditis due to immunotherapy for lung cancer. J Nucl Med Technol 46:260–264CrossRefPubMed

37.

Phelps ME, Huang SC, Hoffman EJ et al (1979) Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-d-glucose: validation of method. Ann Neurol 6:371–388CrossRefPubMed

Titel: Can benign lymphoid tissue changes in 18F-FDG PET/CT predict response to immunotherapy in metastatic melanoma?
verfasst von: Christos Sachpekidis
Lionel Larribère
Annette Kopp-Schneider
Jessica C. Hassel
Antonia Dimitrakopoulou-Strauss
Publikationsdatum: 26.11.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 2/2019
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-018-2279-9

Springer Medizin

Can benign lymphoid tissue changes in ¹⁸F-FDG PET/CT predict response to immunotherapy in metastatic melanoma?